Breaks Categories: News

MondayJun 14, 2021 1:11 pm

PsychedelicNewsBreaks – Microdose Psychedelic Insights’ Upcoming Event to Showcase the Potential of MDMA Therapeutics

Microdose Psychedelic Insights is a cutting-edge conference production company focused around promoting content, financial analysis and engaging events designed to drive the psychedelics industry into the forefront of modern medicine. In partnership with Pharmala Biotech Inc and ACS Pharmacology & Translational Science, Microdose Psychedelic Insights will host the upcoming MDMA Conference: A Molecular Masterclass in an entirely virtual format on June 15, 2021. The event will present a scientific deep dive into the dynamic field of MDMA therapeutics, exploring the potential of MDMA at the intersection of drug development and safety, clinical care and applications, law and regulation, business and…

Continue Reading

MondayJun 14, 2021 9:55 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) CEO to Participate at H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, will be part of the upcoming H.C. Wainwright Psychedelics in Psychiatry and Beyond conference. The all-virtual conference is slated for June 17, 2021. During the conference, Cybin CEO Doug Drysdale will be presenting on Cybin and its business and strategy, as well as a look at where the company stands today. Cybin’s webcast-on-demand presentation will be available starting at 7 a.m. on the morning of June 17, 2021 and will be available for 90 days. In addition to his presentation about Cybin, Drysdale will also be participating…

Continue Reading

FridayJun 11, 2021 3:20 pm

PsychedelicNewsBreaks – InvestorBrandNetwork, PsychedelicNewsWire to Collaborate with Microdose Psychedelic Insights for Upcoming Standout Events

InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, today announced that it, together with its PsychedelicNewsWire (“PNW”) brand, will be collaborating with Microdose Psychedelic Insights for upcoming June conferences. The events slated for later this month include the MDMA Conference, set to be held on June 15, 2021, as well as the Psychedelic Capital Conference, taking place on June 30, 2021. The virtual MDMA Conference will explore the potential of MDMA at the intersection of drug development and safety, clinical care and applications, law and regulation, business and markets, science and research, as well as history and culture. The…

Continue Reading

ThursdayJun 10, 2021 2:44 pm

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Eyes Exciting Month in Commencement of Production, Sales of CBD Gummies

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, is pleased to announce that its wholly owned subsidiary, Pure Extracts Manufacturing Corp., has developed and is in production of innovative, high potency CBD edible gummies for the Canadian market. “June is going to be a very exciting month for us as we commence sales of gummies through our distribution partner,” said Pure Extracts CEO Ben Nikolaevsky. “The edible gummie business is a material revenue producer for Pure Extracts. We plan to replicate the success…

Continue Reading

TuesdayJun 08, 2021 10:59 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Develops New Treatment Model, Announces Co-Sponsorship of First-Ever Trial to Treat Frontline Clinicians

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has developed EMBARK, a transdiagnostic psychotherapy model, and will be co-sponsoring an upcoming trial designed for frontline clinicians experiencing COVID-related distress. Cybin announced that the randomized, placebo-controlled trial will evaluate psychedelic-assisted psychotherapy with psilocybin in the treatment of  symptoms of depression, anxiety, burnout and post-traumatic stress among doctors, nurses and healthcare professionals on the frontlines of COVID-19. EMBARK is a groundbreaking psychotherapy model that integrates leading clinical approaches aimed at promoting supportive healing with psychedelic medicine. Cybin is collaborating with a University of Washington team, led by…

Continue Reading

TuesdayJun 08, 2021 10:31 am

PsychedelicNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Issues Update on Timely Progression of Psychedelic Medicine Program

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today announced that its GMP mescaline synthesis program is on schedule with the completion of initial production batches. According to the update, the industrial-scale manufacture of pharmaceutical-grade psychedelic compounds, including mescaline and psilocybin, is an important part of XPhyto’s psychedelic medicine program and will provide a foundation for its drug formulation and clinical validation work. “With both its North American GMP mescaline synthesis program and German-based psilocybin biotechnology production underway, the first stage of XPhyto’s psychedelic medicine program is progressing on schedule. As the manufacturing programs advance, we look forward to focusing our…

Continue Reading

ThursdayJun 03, 2021 9:59 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Participate at Upcoming LD Micro Invitational XI

Cybin (NEO: CYBN) (OTCQB: CLXPF) CEO Doug Drysdale will be participating at the 2021 LD Micro Invitational XI. The invitational will be held Thursday, June 10. As part of his participation, Drysdale will be presenting a live webcast featuring Cybin, a biotechnology company focused on progressing psychedelic therapeutics. Drysdale’s presentation is scheduled to begin at 3:30 p.m. ET. Interested individuals can register to view the Cybin presentation via the webcast. To view the presentation, visit https://ibn.fm/ZExCT To view the full press release, visit https://ibn.fm/8n2Wj About Cybin Inc. Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics for mental…

Continue Reading

WednesdayJun 02, 2021 11:43 am

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW) to Present at Upcoming H.C. Wainwright Psychedelics Conference

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW), a pharmaceutical company focused on developing compounds for diseases with unmet medical needs through accelerated regulatory pathways, has announced that it will be presenting at H.C. Wainwright & Co.’s Psychedelics in Psychiatry and Beyond conference. The virtual event will be held on June 17, 2021. At the elite conference, Tryp chair and CEO Greg McKee will present an overview of the business including the company’s pipeline, which features its psilocybin-for-neuropsychiatric disorders, or PFN(TM) (“PFN”), program for chronic pain and eating disorder indications. McKee’s prerecorded presentation will be available beginning 7 a.m. EDT…

Continue Reading

TuesdayJun 01, 2021 11:23 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Sponsor Pioneering Study Designed to Expand Understanding of Psychedelic Pharmacotherapy

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced the sponsorship of Kernel’s feasibility study of its Kernel Flow technology to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics. In January 2021, Cybin announced that it would be partnering with Kernel to leverage its proprietary Kernel Flow device for psychedelic-based studies and clinical trials. The first-of-its-kind Kernel Flow device uses quantitative neuroimaging technology that can measure brain activity in real time using a wearable helmet during psychedelic treatments. “We still have much to learn about what is occurring in the brain during a psychedelic…

Continue Reading

FridayMay 28, 2021 10:32 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Present at Upcoming Jefferies Virtual Health Care Conference

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced that its Chief Executive Officer Doug Drysdale will be presenting at the Jefferies Virtual Health Care Conference 2021. Drysdale’s presentation is scheduled to begin at 1:00 p.m. Eastern Time on Tuesday, June 1, 2021. Interested parties should visit https://ibn.fm/Dx6YF to register for the webcast. The presentation will be webcast live via the above link, and a replay will be available for 30 days following the event. To view the full press release, visit https://ibn.fm/9Hc5Z About Cybin Inc. Cybin is a leading biotechnology company focused on…

Continue Reading